Down syndrome (DS) is caused by the triplication of È240 proteincoding genes on chromosome 21 and is the most prevalent form of developmental disability. This condition results in abnormalities in many organ systems, as well as in intellectual retardation. Many previous efforts to understand brain dysfunction in DS have indicated that cognitive deficits are coincident with reduced synaptic plasticity and decreased neuronal proliferation. One therapeutic strategy for optimizing the microenvironment for neuronal proliferation and synaptic plasticity in the brain is the use of neurotrophins to restore the homeostasis of the brain biochemical milieu. Here, we show that peripheral administration of Peptide 6, an 11-mer corresponding to an active region of ciliary neurotrophic factor, amino acid residues 146 to 156, can inhibit learning and memory impairments in Ts65Dn mice, a trisomic mouse model of DS. Longterm treatment with Peptide 6 enhanced the pool of neural progenitor cells in the hippocampus and increased levels of synaptic proteins crucial for synaptic plasticity. These findings suggest a therapeutic potential of Peptide 6 in promoting functional neural integration into networks, thereby strengthening biologic substrates of memory processing.
INTRODUCTION
Down syndrome (DS) is caused by a triplication of human chromosome 21 and results in moderate to profound intellectual disability (1, 2) . Individuals with DS have abnormalities in learning, memory, and language and mental retardation that is essentially universal (3) . Postnatally, the DS brain exhibits degeneration of cortical neurons (4), profound dendritic and synaptic abnormalities (5Y8), and a hypocellular hippocampus and cerebral cortex (9, 10) . Changes in dendritic structure, branching and spine counts, particularly in the hippocampus (11) , seem to contribute substantially to cognitive dysfunction in DS (12) .
The most widely used animal model of DS, the Ts65Dn mouse, is segmentally trisomic for chromosome 16 and carries 3 copies of genes orthologous to those of human chromosome 21 (13, 14) . Ts65Dn mice exhibit several features characteristic of DS, including cognitive impairment (15Y19), alterations in the structure of dendritic spines in cortex and hippocampus (20) , and failed long-term potentiation in the hippocampus and fascia dentata (21Y23). In addition, several studies reported severe impairment of neuronal proliferation in the dentate gyrus of neonate and adult Ts65Dn mice (24Y27).
Neurotrophins comprise a class of factors that not only support the survival of postmitotic neurons but also regulate other neuronal functions, including axonal growth and synaptic plasticity (28Y30). Synaptic plasticity is a key phenomenon in the development and function of neuronal networks and is therefore considered as the cellular substrate of learning and memory (31Y35). Moreover, several lines of evidence support the involvement of neurogenesis in memory processing in the adult brain. In particular, adult-born hippocampal neurons have been associated with complex forms of spatial or associative memory (36Y39). Therefore, adjusting the brain milieu by modulating neurotrophins seems to be a promising therapeutic strategy to thwart neurodevelopmental abnormalities, neurodegeneration, and cognitive impairment associated with DS.
In an effort to enhance neuronal plasticity in Ts65Dn mice, we enriched the brain biochemical milieu with an 11-mer peptide, Peptide 6, corresponding to amino acid residues 146 to 156, an active region of ciliary neurotrophic factor (CNTF). Peptide 6 is blood-brain barrier permeable and modulates the CNTF pathway by inhibiting the antineurogenic activity of leukemia inhibitory factor, thereby increasing neurogenesis (40) . active region of this neurotrophic factor by epitope mapping of neutralizing antibodies to CNTF (40) . The peptide was synthesized on a commercial basis by the Pan Biotechnology Facility of Stanford University (Palo Alto, CA).
Animals and Housing
Female Ts65Dn mice carrying a partial trisomy of chromosome 16 (18) were obtained from Jackson Laboratories (New Harbor, ME) and maintained keeping the original genetic background by mating them with C57BL/6JEi Â C3SnHeSnj (B6EiC3) males. Mice were housed and bred in accordance with approved protocols from our Institutional Animal Care and Use Committee, according to the PHS Policy on Human Care and Use of Laboratory Animals (revised March 15, 2010) . This study was performed on heterozygous Ts65Dn female mice. When genotyped, each animal was checked for retinal degeneration. Mice carrying the gene for retinal degeneration were not used in the study. Control animals were nontrisomic (2N) littermate mice. Animals were group-housed (4 animals per cage) with a 12:12-hour lightdark cycle and with ad libitum access to food and water.
Treatment of Animals With Peptide 6
Female Ts65Dn mice 11-to 15-month-old (n = 8) and 2N female littermates (n = 8) received subcutaneous implants of extended release depot pellets containing Peptide 6 (Innovative Research of America, Sarasota, FL) for 30 days of continuous dosing (50 nmol per mouse per day). The dosage was chosen according to the titrations studied in previous work (40) . For control groups, the pellets consisted of the carrier biopolymer only (Ts65Dn, n = 7; 2N, n = 7). For implantation, mice were anesthetized with 2.5% Avertin (0.38 ml for a 25-g animal; Sigma Aldrich). Under sterile conditions, pellets were subcutaneously implanted along the anterolateral aspect of the right shoulder with a precision trochar (Innovative Research of America). Animals were then transferred to the animal colony after recovery from anesthesia. There were no complications associated with the implantation and treatment. To investigate neural progenitor cell proliferation, bromodeoxyuridine (BrdU) was given as 2 daily intraperitoneal injections (75 mg/kg per dose) for 5 days starting on Day 4 of treatment with Peptide 6 (Fig. 1B) .
Behavioral Procedures General Examination
The physical state and condition of animals were carefully checked throughout the treatment by evaluating grooming, posture, physical state, and clasping reflex. Body weights were also recorded.
Prehensile Traction Test
At the end of the treatment period, prehensile traction force was evaluated measuring fall latency of the mouse suspended with its forepaws from a string suspended 60 cm from a padded surface.
Spatial Reference Memory Task
Before training, mice were handled gently for 2 to 3 min/d for 3 days to minimize nonspecific stress. Spatial reference memory testing was started on the last week of treatment (Fig. 1B) . Spatial reference learning and memory were evaluated in the water maze using a procedure adapted from Morris et al (41) . The test required that mice used a spatial navigational strategy based on a spatial representation of the environment to find a fixed submerged platform. The procedure was performed in a 110-cm-diameter circular tank. The pool was filled with water (21-C T 1-C) made opaque by adding white nontoxic paint. Acquisition was started with the escape platform (10-cm-diameter submerged 1 cm below water surface) in the Northwest quadrant; each animal was given 60 seconds to find the platform. If the mouse did not find the platform in 60 seconds, it was gently guided to it. At the end of each trial, the mouse was left on the platform for 20 seconds, then dried and returned to its home cage until the next trial. Five such acquisition trials were given on each day for 4 consecutive days. A test for retention, or probe trial, was given 24 hours later. During the probe trial, the mouse was allowed to swim in the tank without the escape platform for 60 seconds.
The learning measures were the time and distance covered to reach the escape platform. Swim speed was also calculated. For the probe trial, the tank was divided into 4 imaginary quadrants and a small zone where the escape platform was located. The measures for retention were the percent of time spent in each quadrant and the number of crossings of the platform zone. Behavior in the water maze was monitored by a Samsung Digital Camera (SDC 4304, San Diego Instruments, San Diego, CA) mounted to the ceiling and tracked and timed by a SMART (Pan Lab/San Diego Instruments) version 2.0.14 software.
Tissue Processing
Within 90 minutes after completion of the behavioral task, animals were anesthetized with an overdose of sodium pentobarbital (125 mg/kg) and transcardially perfused with 0.1 mol/L phosphate-buffered saline (PBS). After perfusion, the brains were removed, and the hippocampus, a portion of the cortex, the cerebellum, and thalamic nuclei were dissected from the left hemisphere and immediately frozen in dry ice for biochemical analysis. The right hemisphere was fixed in 4% paraformaldehyde in 0.1 mol/L PBS for at least 24 hours at room temperature. Tissues were then postfixed in a 30% sucrose solution at 4-C overnight. Forty-micrometer sagittal sections of the entire hippocampus were cut on a freezing microtome. The sections were stored in glycol antifreeze solution (ethylene glycol, glycerol, and 0.1 mol/L PBS in 3:3:4 ratio) at j20-C until further processing.
Immunohistochemistry
For the immunohistochemical study, 4 animals per group were randomly selected and analyzed. Immunohistochemistry was performed on free-floating sections as described (42) . Briefly, every 10th section was chosen for densitometry (,5Y6 sections per animal), and every 5th brain section was chosen for quantification of newborn cells (,10Y11 sections per animal).
The following primary antibodies were used: SMI52 to the adult isoforms of microtubule-associated protein 2 (MAP2, MAP2a/b, 1:1000; Covance, Princeton, NJ); antipostsynaptic density protein 95 (PSD95; Cell Signaling Technology, Danvers, MA); antiYglutamate receptors 2/3 (GluR2/3; Abcam, Cambridge, MA), anti-Zif268 (1:500; Calbiochem, San Diego, CA), and anti-BrdU (1:400; Accurate, Westbury, NY). The following secondary antibodies were used: Alexa 488Yconjugated goat anti-mouse immunoglobulin G antibody (1:500; Molecular Probes, Carlsbad, CA) and Alexa 594Yconjugated goat anti-rabbit immunoglobulin G antibody (1:500; Molecular Probes).
Densitometry and Stereology
For MAP2 and PSD95 densitometry, the region of interest was outlined at a magnification of 20Â; the entire area of the CA1, the CA3, and the dentate gyrus (DG) of the hippocampus and parietal association cortex was analyzed. Maximum projection images were then generated based on confocal z stacks, and the antibody staining was quantified by measuring mean pixel intensity with the software ImageProPlus 5.0 (Media Cybernetics, Silver Spring, MD).
Zif268-and GluR2/3-positive cells were counted using Stereo Investigator software (Microbrightfield, Inc, Williston, VT). Areas of interest were traced at low magnification with a 10Â objective, and counting frames were selected at random by the software. An optical fractionator method was used to estimate the number of positive cells at high magnification with a 40Â objective. This technique involved counting neurons with an optical dissector, a 3-dimensional probe placed through a reference space (43) . This method is independent of volume measurements and is therefore unaffected by tissue shrinkage. A total of 3 to 4 sections per region were analyzed, and the final cell counts were expressed as cells per cubic millimeter. Neurons were considered stained when their edges lay within the dissector area and they did not intersect forbidden area. The guard zone thickness was set as 2 Km.
Neural progenitor cell proliferation was assessed in the DG by counting the number of BrdU-immunoreactive (BrdU-IR) cells in various layers of the DG. The granule cell layer (GCL) was subdivided into inner and outer halves. The inner GCL consisted of the subgranular zone, defined as a 2-to 3-nuclei-thick layer bordering the inner half of the GCL adjacent to the hilus; the outer GCL (oGCL) was defined as the half of the GCL adjacent to the molecular layer. A cell in the middle of the GCL was considered part of the subgranular zone; a cell bordering the GCL in the molecular layer was included in oGCL counts. The molecular layer was defined as the region between the superior limb of GCL and hippocampal fissure and between the inferior limb of the GCL and the inferior borders of the DG. The hilus included the superficial polymorphic layer. Counting was performed using 40Â oil objective of a Nikon 90i fluorescent microscope equipped with Nikon C1 3-laser confocal system and a Nikon DS U1 digital camera. Using principles of unbiased stereology, the optical fractionator method was used to estimate cell counts for the DG (43) . The total number of neurons (N) for each brain was estimated as: N = $Qj Â 1/t sf Â 1/a sf Â 1/s sf , where t sf was the thickness sampling fraction, a sf was the area sampling fraction, and s sf was the section sampling fraction. $Qj was the total number of cells actually counted in the dissectors that fell within the sectional profiles of the region of interest within sampled sections. All layers of the DG described previously were analyzed separately for cell counts. For each brain, at least 100 cells were counted based on coefficient of error determinations.
Western Blots
Hippocampi were homogenized to generate 10% (wt/ vol) homogenate in buffer containing 50 mmol/L Tris-HCl (pH 7.4), 8.5% sucrose, 2 mmol/L EDTA, 2 mmol/L EGTA, 10 mmol/L A-mercaptoethanol, 5 mmol/L benzamidine, 0.5 mmol/L AEBSF, 4 Kg/ml pepstatin A and 10 Kg/ml each of aprotinin and leupeptin, 20 mmol/L A-glycerol phosphate, 100 mmol/L sodium fluoride, 1 mmol/L sodium vanadate, and 100 nmol/L okadaic acid. The protein concentration was measured by the modified Lowry assay (44) . The tissues were then boiled in Laemmli sample buffer in a water bath for 5 minutes and subjected to 10% sodium dodecyl sulfateY polyacrylamide gel electrophoresis and Western blots. The blots were developed with rabbit monoclonal antibodies to CREB and phospho-CREB (1:1000; Cell Signaling Technology). Immunoreactive protein bands were visualized with chemiluminescence reagents (Thermo Scientific, Rockford, IL), and the films were scanned and analyzed using MultiGauge V3 software (Fuji Photo Film, Tokyo, Japan).
Statistics
Statistical analyses were conducted with SASv5 (SAS Institute, Cary, NC). Data are presented as mean T SEM. For analysis involving multiple groups, analysis of variance (ANOVA) with post hoc Tukey or Fisher test were used. For all other comparisons (including intergroup comparisons), Student t-test was used. Differences with p G 0.05 were considered significant. Data from 2N animals treated with vehicle or Peptide 6 were pooled because no significant differences were observed between these 2 groups.
RESULTS

General Behavioral Observations
Administration of the full-length CNTF protein in human clinical trials is known to cause anorexia, skeletal muscle loss, hyperalgesia, severe cramps, and muscle pain (45, 46) . Therefore, we carefully checked the physical state and general behavior of animals throughout the study period. We did not observe any alterations in general physical state, including grooming, posture, and clasping reflex, due to either the genotype or the treatment with Peptide 6. Statistical analysis did not reveal any significant group effect or group Â treatment effect in body weight ( Fig. 1C ; ANOVA, p = 0.935). Similarly, no differences of forepaw strength measured as fall latency in prehensile traction test ( Fig. 1D ; ANOVA, p = 0.870) or swim speed in the water maze ( Fig. 1E ; ANOVA, p = 0.195) were observed among groups. These data suggested that the genotype as well as the treatment with Peptide 6 did not induce any significant effect on general behavior.
Effect of Treatment With Peptide 6 on Learning and Memory
The spatial reference memory task assesses hippocampal-dependent reference memory in rodents, requiring that mice use a spatial navigational strategy to find a fixed submerged escape platform. The hippocampal system processes information on the relationships among distal environmental cues into a spatial map where spatial coordinates of the submerged platform are encoded (41) . The hippocampus is also crucial for memory storage, consolidation, and restitution of the spatial information (47) .
Performance of animals during training was analyzed as latency to reach the submerged platform (Fig. 1F) . Statistical analysis revealed a significant group effect (ANOVA, p G 0.001), suggesting significant difference of learning among groups. Post hoc analyses showed that wild-type mice displayed significantly better performance than Ts65Dn mice (Fisher test, p G 0.001). Separate analysis of learning for each group revealed that 2N animals and Ts65Dn mice treated with Peptide 6 significantly improved performance across days (ANOVA, p G 0.007), whereas Ts65Dn mice treated with vehicle only did not (ANOVA, p = 0.175). These results reflected that Ts65Dn mice presented a strong impairment of learning and that treatment with Peptide 6 alleviated this deficit albeit not restoring performance to control levels.
Analysis of the test for retention of learned information (probe trial) was conducted on the percentage of time animals spent in the target quadrant (Fig. 1G ) and on the number of crossings of the platform zone (Fig. 1H) . Ts65Dn mice neither preferentially visited the target quadrant compared with 2N mice ( Fig. 1G ; Student t-test, p = 0.007) nor crossed the platform zone ( Fig. 1H ; Student t-test, p G 0.001). These results confirmed the deficit of learning observed during the training of the task and showed compromised retention in Ts65Dn mice. Performance of Peptide 6Ytreated Ts65Dn mice was similar to that of 2N animals ( Fig. 1G ; Student t-test, p = 0.636; Fig. 1H ; Student t-test, p = 0.121) and was significantly improved compared with vehicle-treated Ts65Dn mice ( Fig. 1G ; Student t-test, p = 0.024; Fig. 1H ; Student t-test, p = 0.018). These results suggested that, although Ts65Dn mice treated with Peptide 6 did not display as good a performance as 2N animals did during the training, they encoded, stored, and/or remembered the spatial coordinates of the platform within the environment. Overall, these results showed that treatment with Peptide 6 rescued both learning and memory impairments of Ts65Dn mice.
Effect of Treatment With Peptide 6 on Neuronal Plasticity
Previously, we reported that Peptide 6 was blood-brain barrier permeable and improved cognitive function of C57BL/ 6 normal adult mice as well as enhanced neuronal plasticity and neurogenesis through the CNTF pathway by inducing the inhibition of leukemia inhibitory factor (40) . Because in the present study we found alleviation of cognitive impairment by treatment with Peptide 6 in Ts65Dn mice, we investigated the effect of this peptide on neuronal plasticity and neural progenitor cell proliferation. We analyzed the effect of treatment with Peptide 6 on MAP2, PSD95, and GluR2/3 expression because an abnormal expression of these postsynaptic proteins that are critical for synaptic plasticity was previously reported in Ts65Dn mice (48) .
Microtubule-associated protein 2 is a neuron-specific cytoskeletal protein involved in microtubule assembly and stabilization of dendritic shape, an essential step during neuron development and synaptic plasticity. We found a dramatic decrease of MAP2 immunoreactivity in the hippocampus of Ts65Dn mice versus 2N controls ( Fig. 2A ; Student t-test, p = 0.023). In Ts65Dn mice treated with Peptide 6, however, MAP2 immunoreactivity was significantly increased in the hippocampus (Student t-test, p = 0.047) and reached the control level (Student t-test, p = 0.439).
PSD95, a core structural postsynaptic protein critical for the tethering of AMPA-type glutamate receptors (49) , plays a decisive role in controlling synapse strength and activitydependent plasticity (50, 51) . We observed a significant decrease of PSD95 immunoreactivity in the hippocampus of Ts65Dn versus 2N mice ( Fig. 2B ; Student t-test, p = 0.010), and treatment with Peptide 6 increased PSD95 immunoreactivity to control level (Student t-test, p = 0.428).
GluR2/3 are selective AMPA receptors that play a functional role in hippocampal learning, mediating changes in synaptic strength that occurs after plasticity has been established by N-methyl-d-aspartate receptors (52) . Analyses of GluR2/3 immunoreactivity showed a marked reduction in the hippocampi of Ts65Dn versus 2N mice ( Fig. 2C ; Student t-test, p = 0.023) and that treatment with Peptide 6 in Ts65Dn mice restored the GluR2/3 immunoreactivity (Student t-test, p = 0.010) to control level (Student t-test, p = 0.414).
Effect on Activation of Immediate Early Genes
The expression of Zif268 and pCREB immediate early genes reflect neuronal activity associated with the induction of plasticity underlying memory consolidation (53) . Analysis of Zif268 by immunohistochemistry (Fig. 2D) and of CREB and pCREB by Western blots (Fig. 2E ) after the water maze task revealed a general pattern of their reduction in the hippocampi of Ts65Dn mice that was alleviated by treatment with Peptide 6. Together, these findings on MAP2, PSD95, GluR2/3, and immediate early genes Zif268 and pCREB suggest a deficiency of neuronal plasticity in Ts65Dn mice that was rescued by long-term treatment with Peptide 6.
Effect on Neural Progenitor Cell Proliferation
The number of BrdU-IR cells was dramatically decreased in the DG in Ts65Dn versus 2N mice (Fig. 3A, B ; Student t-test, p G 0.001). In Peptide 6Ytreated Ts65Dn mice, the number of BrdU-IR cells was significantly increased compared with vehicle-treated Ts65Dn mice (Student t-test, p = 0.008) and not significantly different from 2N controls (Student t-test, p 9 0.050). Analysis of BrdU-IR cells in the sublayers of the DG revealed that, in the inner GCL, there was a marked decrease in the number of BrdU-IR cells in Ts65Dn mice compared with 2N animals (Student t-test, p G 0.001) (Fig. 3C) . This decline was prevented in Peptide 6Ytreated Ts65Dn mice (Student t-test, p = 0.004). In the oGCL, no difference in the number of the BrdU-IR cells was observed among groups (Fig. 3D) . In the hilus, there was a significant reduction of the number of the BrdU-IR cells in Ts65Dn mice versus 2N controls ( Fig. 3E ; Student t-test, p = 0.017) but no significant effect of Peptide 6 treatment. In the molecular cell layer, there was a marked diminution of the number of BrdU-IR cells in Ts65Dn mice versus 2N mice ( Fig. 3F ; Student t-test, p = 0.009), which was rescued by Peptide 6 treatment (Student t-test, p = 0.031). Normally, only È25% of the total BrdU-IR cells in the GCL are present in the oGCL. An increase of progenitor cells in the oGCL could be a result of ectopic birth, a phenomenon referring to an abnormal and selective increase in proliferation of progenitors in the oGCL that may cause abnormal connectivity (54) . Statistical analysis conducted on the calculated index of ectopic birth (%) did not show any difference among groups (data not shown). These findings showed a reduction of proliferation of neural progenitor cells in Ts65Dn mice in the DG and that longterm treatment with Peptide 6 rescued this cell proliferation abnormality.
DISCUSSION
Down syndrome produces a variable set of clinical features, but mental retardation remains an invariable hallmark and the most invalidating aspect of the disease with a major impact on public health. The Ts65Dn trisomic mouse model exhibits a broad range of DS characteristics, including defects in synapse formation, neurophysiology and signaling pathways, neurogenesis deficit, and cognitive impairment. Accumulating evidence raises the exciting possibility that pharmacological regulation of neurotrophins can correct the homeostasis of the brain biochemical milieu. The present study shows for the first time that peripheral administration of Peptide 6 can shift the expression of dendritic and postsynaptic proteins MAP2, PSD95, and GluR2/3, as well as correct neuronal progenitor proliferation, and thereby rescue cognition in Ts65Dn mice. Our previous studies showed that Peptide 6, which corresponds to an active region of CNTF and is blood-brain barrier permeable, can enhance neurogenesis by antagonizing leukemia inhibitory factor (40) . These findings suggested the therapeutic potential for Peptide 6 to correct impairments in neural cell proliferation and synaptic plasticity and consequent cognitive deficits in Ts65Dn mice. Previous studies showed that long-term treatment with memantine (55) or estrogen replacement therapy (56) alleviated cognitive impairment in Ts65Dn mice and increased levels of neurotrophins. On the other hand, it has been shown that treatment of Ts65Dn mice with fluoxetine (57) or lithium (58) increased neurogenesis.
In the present study, treatment with Peptide 6 did not induce weight loss, modification of general behavior, or any other apparent deleterious adverse effects. This observation is crucial because administration of CNTF induced serious adverse effects including anorexia, skeletal muscle loss, hyperalgesia, cramps, and muscle pain in clinical trials, and antibodies to CNTF were detected in the plasma of the treated individuals (59) .
In the spatial reference memory task, the hippocampus is crucial for processing information on relationships among distal environmental cues into a spatial map (41) and is also essential for memory storage, consolidation, and restitution of the spatial information (47) . We observed that, in Ts65Dn mice, learning and memory performances were dramatically impaired compared with 2N controls. These results are in agreement with previous studies (17, 18, 60) and show that trisomic animals were not able to encode, store, and/or recognize spatial representation of the environment and coordinates of the submerged platform. Long-term treatment with Peptide 6 alleviated these deficits. We observed that, along with the improvement of spatial learning capabilities, treatment with Peptide 6 also alleviated spatial memory, increasing Ts65Dn mice's performance to control levels in the probe trial. These results suggested that treatment with Peptide 6 enhanced memory consolidation mechanisms.
Synaptic plasticity, or the long-lasting alterations in the efficacy of synaptic connections between 2 neurons, is thought to be the cellular substrate of memory (31Y35). It is now widely reported that cognitive deficits in Ts65Dn mice are strongly associated with alterations in the structure of dendritic spines in the hippocampus and the cortex (20) , failure of long-term potentiation in the hippocampus and fascia dentate (21Y23), and abnormal expression of synaptic proteins in the hippocampus (48) . In the present study, we found that treatment with Peptide 6 positively regulated MAP2, PSD95, and GluR2/3 AMPA receptor expression in the hippocampus of Ts65Dn mice. These proteins are critically involved in the glutamate excitatory pathway of longterm synaptic plasticity and long-term memory. Glutamate regulation of MAP2 phosphorylation transduces neural activity into modifications in dendritic structure (61, 62) . PSD95 anchors AMPA-type glutamate receptors (49) and participates in AMPA receptor delivery during experience-driven plasticity and long-term potentiation (51) . AMPA receptors play a functional role in hippocampal learning, mediating changes in synaptic strength that occurs after plasticity has been established by N-methyl-D-aspartate receptors (52) . Together, our results suggest that Peptide 6 can regulate expression of postsynaptic proteins playing central role for synaptic strengthening induced by experience-driven plasticity.
Immediate early genes, and more specifically Zif268 and CREB, are considered markers of neuronal activity associated with the induction of plasticity underlying memory consolidation (53). We observed that the level of expression of these proteins induced by a cognitive stimulation tends to decrease in Ts65Dn mice but that treatment with Peptide 6 restored Zif268 and pCREB after cognitive stimulation to control levels. These observations therefore confirmed the beneficial effect of treatment with Peptide 6 in Ts65Dn mice, alleviating learning and memory impairments and thus might be driven by enhancing neuronal plasticity.
In addition to weakness of synaptic plasticity, several studies report severe neuronal proliferation impairment in the dentate gyrus of neonate and adult Ts65Dn mice (24, 25, 27, 58) . Because this neurogenesis impairment is reported as early as embryonic stages in Ts65Dn mice (26) , such altered embryonic brain development may underlie postnatal defects. Consistent with these studies, we observed a dramatic decrease of BrdU-IR cells in the dentate gyrus of Ts65Dn mice that was rescued by Peptide 6. It is now widely reported that neurogenesis is vulnerable to pathologic conditions (63Y66), resulting in a decline in the ability of neurons to modify their connectivity in response to environmental and physiological stimuli contributing to reduction in memory function. Imbalances of neurotrophins have dramatic repercussions on proliferation of neural progenitor cells (67Y69), whereas exogenous addition of growth factors such as insulin-like growth factor 1 (70), epidermal growth factor, and fibroblast growth factor (71) or a reduction of corticosteroid levels by adrenalectomy (72) can, at least partially, restore the rate of neural stem cell proliferation. Therefore, it is reasonable to speculate that enriching the brain biochemical milieu can trigger appropriate signals for neurogenesis.
Individuals with DS develop Alzheimer disease histopathology in their fourth decade of life in 100% of cases (73, 74) . In Ts65Dn mice, an increase of amyloid precursor protein levels (75) without increase of AA 1Y40 and AA 1Y42 (76) was reported from 10 months of age, as well as clusters of extracellular granules that are positive for tau and reelin (77) . In a previous study, we reported that Peptide 6 did not have any significant effect on moderate stages of AA and tau pathologies in a 3ÂTg-AD mouse model of Alzheimer disease (78) . Therefore, we believe that, in the present study, a beneficial effect of treatment with Peptide 6 is unlikely to be due to the reduction of AA and tau pathologies in Ts65Dn mice.
In conclusion, we observed that long-term treatment with Peptide 6 rescued the commonly described features of Ts65Dn mice, including learning and memory deficits, failure of hippocampal synaptic plasticity, and impairment of neurogenesis. Peptide 6 treatment enhanced memory consolidation, acted on proteins that are critically involved in strengthening of synaptic plasticity, and increased the pool of neurons potentially recruited into the network of information processing by promoting neuronal precursor proliferation.
